Economic Evaluation of Treatment Options in Patients with Alzheimerʼs Disease

Cost-Effectiveness of Donepezil in the Treatment of Mild or Moderate Alzheimer's Disease

(2017) Julio López-Bastida et al.   JOURNAL OF ALZHEIMERS DISEASE

Cost-Effectiveness: Cholinesterase Inhibitors and Memantine in Vascular Dementia

(2014) Camilla L. Wong et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Alzheimer's disease: clinical trials and drug development

(2010) Francesca Mangialasche et al.   LANCET NEUROLOGY

Cost Effectiveness of Donepezil in the Treatment of Mild to Moderate Alzheimerʼs Disease

(2010) Denis Getsios et al.   PHARMACOECONOMICS

A Systematic Review to Assess the Policy-Making Relevance of Dementia Cost-of-Illness Studies in the US and Canada

(2010) Mark Oremus et al.   PHARMACOECONOMICS

Cost-of-illness studies of dementia: a systematic review focusing on stage dependency of costs

(2009) W. Quentin et al.   ACTA PSYCHIATRICA SCANDINAVICA

Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model

(2009) Masashi Kasuya et al.   ARCHIVES OF GERONTOLOGY AND GERIATRICS

Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies

(2009) Anders Gustavsson et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

The Cost of Dementia in Europe

(2009) Linus Jönsson et al.   PHARMACOECONOMICS

Modeling the Cost-Effectiveness of Galantamine for Mild to Moderately Severe Alzheimer's Disease in Korea

(2009) Guk-Hee Suh   VALUE IN HEALTH

A Markov Model of the Cost Effectiveness of Olanzapine Treatment for Agitation and Psychosis??in Alzheimer??s Disease

(2008) Stephanie Kirbach et al.   CLINICAL DRUG INVESTIGATION

Systematic review of economic evaluations of Alzheimer’s disease medications

(2008) Mark Oremus   Expert Review of Pharmacoeconomics & Outcomes Research